Geratherm Medical AG: Geratherm Medical report preliminary (unaudited) 2019 business figures
Geratherm Medical AG / Key word(s): Preliminary Results
Publication of an insider information pursuant to article 17 of MAR
Geratherm Medical report preliminary (unaudited) 2019 business figures
- Sales 19.9 million EUR -7.8 %
- EBITDA 2,577 k EUR -8.0 %
- EBIT 1,273 k EUR -36.0 %
- EAT 546 k EUR -52.7 %
- Result per share 11 cents
- Dividend proposal 25 cents per unit share
- Conversion of sales of apoplex medical to the entire contract term (IFRS delimitation) results in one-off strain in sales (-205 k EUR) and impact on earnings (-568 k EUR, incl. deferred tax burden amounting to 314 k EUR)
- Strong sales and earnings growth expected for 2020
Geratal, March 31, 2020 - Geratherm Medical record for the 2019 fiscal year a drop in sales of -7.8 % to 19.9 million EUR on a consolidated basis. The Healthcare Diagnostic core business (66.0 % of the group sales) could report a solid growth of + 5.1 %. The one-off special charges were due to apoplex medical, where the present sales had to be delimited according to IFRS over the entire term of the hospital contracts concluded. The one-off effect led to a decline in sales of 205 k EUR and an impact on earnings of 568 k EUR, of which 313 k EUR are for the passive deferred tax liabilities for development services. Due to product conversions, the LMT Medical subsidiary showed postponements of orders to the 2020 fiscal year resulting in a decline in sales of 1,409 k EUR and an impact on earnings of 467 EUR on group level.
The 2019 special charges should not occur again in this form for the 2020 fiscal year. Due to the Corona pandemic, Geratherm Medical had a strong start into the new fiscal year. The clinical thermometer production is being increased by 30 %. At present the demand cannot be satisfied. There is evidence that the pulmonary function of patients after a hospital stay due to Corona could be limited. Geratherm Respiratory sell pulmonary function measuring instruments for diagnosing late effects. In the first quarter the sales rose by 30 %. At present there is an increased number of incoming orders from China. We can expect that other countries will follow. The new factory building in Bad Kissingen provides the respective production capacities.
Geratherm Medical expect significantly higher reported sales and earnings for the 2020 fiscal year.
The detailed annual report will be published on April 23, 2020.
Geratherm Medical AG
Dr. Gert Frank
31-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Geratherm Medical AG|
|Phone:||+49 (0)36205 98-0|
|Fax:||+49 (0)36205 98-1 15|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1012147|
|End of Announcement||DGAP News Service|